共 312 条
[1]
3rd Burris HA(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-2413
[2]
Moore MJ(2011)Molecular predictors of gemcitabine response in pancreatic cancer World J Gastrointest Oncol 3 153-164
[3]
Andersen J(2009)Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer Gastroenterology 136 187-195
[4]
Green MR(2014)Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial J Natl Cancer Inst 106 djt347-674
[5]
Rothenberg ML(2012)Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma Gastroenterology 143 664-312
[6]
Modiano MR(2014)Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis Genet Test Mol Biomark 18 306-2497
[7]
Cripps MC(2006)Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival Clin Cancer Res 12 2492-4572
[8]
Portenoy RK(2009)The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase Cancer Res 69 4567-394
[9]
Storniolo AM(2007)Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas J Gastroenterol 42 389-8490
[10]
Tarassoff P(2014)hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review World J Gastroenterol 20 8482-111